Recent acquisitions of small drugmakers are giving biotechnology venture capitalists hope for stabilization in their industry following two years of declining investment. Purchases this week followed a busy fourth quarter for biotech mergers and acquisitions, providing venture capitalists with returns as few companies are going public. Copyright ©2024 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
This content was originally published here.
